Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Mar 13;23(1):100.
doi: 10.1186/s12882-022-02727-5.

Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial

Mabel Aoun  1   2 , Ghassan Sleilaty  3 , Celine Boueri  4 , Eliane Younes  5 , Kim Gabriel  6 , Reine-Marie Kahwaji  4 , Najla Hilal  4 , Jenny Hawi  4 , Rita Araman  7 , Dania Chelala  3 , Chadia Beaini  3   8
Affiliations
Multicenter Study

Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial

Mabel Aoun et al. BMC Nephrol. .

Abstract

Background: Treatment with erythropoietin is well established for anemia in chronic kidney disease patients but not well studied in acute kidney injury.

Methods: This is a multicenter, randomized, pragmatic controlled clinical trial. It included 134 hospitalized patients with anemia defined as hemoglobin < 11 g/dL and acute kidney injury defined as an increase of serum creatinine of ≥ 0.3 mg/dL within 48 h or 1.5 times baseline. One arm received recombinant human erythropoietin 4000 UI subcutaneously every other day (intervention; n = 67) and the second received standard of care (control; n = 67) during the hospitalization until discharge or death. The primary outcome was the need for transfusion; secondary outcomes were death, renal recovery, need for dialysis.

Results: There was no statistically significant difference in transfusion need (RR = 1.05, 95%CI 0.65,1.68; p = 0.855), in renal recovery full or partial (RR = 0.96, 95%CI 0.81,1.15; p = 0.671), in need for dialysis (RR = 11.00, 95%CI 0.62, 195.08; p = 0.102) or in death (RR = 1.43, 95%CI 0.58,3.53; p = 0.440) between the erythropoietin and the control group.

Conclusions: Erythropoietin treatment had no impact on transfusions, renal recovery or mortality in acute kidney injury patients with anemia. The trial was registered on ClinicalTrials.gov (NCT03401710, 17/01/2018).

Keywords: Acute kidney injury (AKI); Anemia; Death; Dialysis; Erythropoietin (EPO); Hemoglobin; Randomized pragmatic clinical trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CONSORT flow diagram
See this image and copyright information in PMC

References

    1. Eschbach JW, Abdulhadi MH, Browne JK. Recombinant human erythropoietin in anemic patients with end-stage renal disease Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000. doi: 10.7326/0003-4819-111-12-992. - DOI - PubMed
    1. Bernieh B. Viral hepatitis in hemodialysis: An update. J Transl Int Med. 2015;3(3):93–105. doi: 10.1515/jtim-2015-0018. - DOI - PMC - PubMed
    1. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482–1493. doi: 10.2215/CJN.00710113. - DOI - PMC - PubMed
    1. António Lopes J, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clinical Kidney Journal. 2013;6(1):8–14. doi: 10.1093/ckj/sfs160. - DOI - PMC - PubMed
    1. Hales M1, Solez K, Kjellstrand C. The anemia of acute renal failure association with oliguria and elevated blood urea. Ren Fail. 1994;16(1):125–31. doi: 10.3109/08860229409044854. - DOI - PubMed

Publication types

Associated data